Retrospective analysis of adjuvant therapy with dabrafenib and trametinib for 24 patients with malignant melanoma
Background and purpose: Melanoma is the most lethal cutaneous malignant tumor. Patients with resected stage Ⅲ melanomas have a high risk of recurrence after surgery. This study retrospectively analyzed the efficacy and safety of dabrafenib combined with trametinib in the adjuvant setting for stage Ⅲ...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Editorial Office of China Oncology
2022-12-01
|
| Series: | Zhongguo aizheng zazhi |
| Subjects: | |
| Online Access: | http://www.china-oncology.com/fileup/1007-3639/PDF/1675314921307-882219677.pdf |
| _version_ | 1811168726415835136 |
|---|---|
| author | JIA Dongdong, LI Tao |
| author_facet | JIA Dongdong, LI Tao |
| author_sort | JIA Dongdong, LI Tao |
| collection | DOAJ |
| description | Background and purpose: Melanoma is the most lethal cutaneous malignant tumor. Patients with resected stage Ⅲ melanomas have a high risk of recurrence after surgery. This study retrospectively analyzed the efficacy and safety of dabrafenib combined with trametinib in the adjuvant setting for stage Ⅲ melanoma patients with BRAF mutation in China. Methods: A retrospective analysis was performed on 24 patients with stage Ⅲ cutaneous and acral malignant melanoma who received adjuvant treatment with trametinib and dabrafenib in Zhejiang Cancer Hospital from August 2019 to April 2022. Results: Of the 24 patients, 7 were stage Ⅲ B, 11 were stage Ⅲ C, 3 were stage Ⅲ D, and 3 were stage Ⅲ (the specific stage was unknown). As of October 1, 2022, 12 patients (50.0%) had completed the protocol for one year. Of the 24 patients, 5 (20.8%) patients relapsed. The The 1-year recurrence-free survival (RFS) rate was 76.2% (95% CI: 65.2%-87.2%). In the cutaneous melanoma subgroup, the 1-year RFS rate was 81.6% (95% CI: 71.6%-91.6%). Two patients relapsed during adjuvant therapy, and three patients relapsed after completing the protocol. Twenty patients (83.3%) reported at least one adverse event, of which 7 patients (29.2%) had grade 3 or grade 4 serious adverse reactions. The most common adverse reactions were fever, fatigue and nausea. Panniculitis occurred in 4 patients, mainly involving thighs and upper limbs. One patient (4.2%) permanently stopped taking the drug due to adverse events, the dose was adjusted in 2 patients (8.3%) due to adverse events, and drug treatment was interrupted in 7 patients (29.2%) due to adverse events. Conclusion: This study confirmed the short-term benefit and good tolerance of the adjuvant therapy with dabrafenib combined with trametinib in Chinese patients with stage Ⅲ melanoma with BRAFV600 mutation. |
| first_indexed | 2024-04-10T16:30:26Z |
| format | Article |
| id | doaj.art-b874f2bea89044b597eec3ee40a43fe6 |
| institution | Directory Open Access Journal |
| issn | 1007-3639 |
| language | English |
| last_indexed | 2024-04-10T16:30:26Z |
| publishDate | 2022-12-01 |
| publisher | Editorial Office of China Oncology |
| record_format | Article |
| series | Zhongguo aizheng zazhi |
| spelling | doaj.art-b874f2bea89044b597eec3ee40a43fe62023-02-09T00:26:00ZengEditorial Office of China OncologyZhongguo aizheng zazhi1007-36392022-12-0132121178118310.19401/j.cnki.1007-3639.2022.12.005Retrospective analysis of adjuvant therapy with dabrafenib and trametinib for 24 patients with malignant melanomaJIA Dongdong, LI Tao0Department of Bone and Soft-tissue Surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310005, Zhejiang Province, ChinaBackground and purpose: Melanoma is the most lethal cutaneous malignant tumor. Patients with resected stage Ⅲ melanomas have a high risk of recurrence after surgery. This study retrospectively analyzed the efficacy and safety of dabrafenib combined with trametinib in the adjuvant setting for stage Ⅲ melanoma patients with BRAF mutation in China. Methods: A retrospective analysis was performed on 24 patients with stage Ⅲ cutaneous and acral malignant melanoma who received adjuvant treatment with trametinib and dabrafenib in Zhejiang Cancer Hospital from August 2019 to April 2022. Results: Of the 24 patients, 7 were stage Ⅲ B, 11 were stage Ⅲ C, 3 were stage Ⅲ D, and 3 were stage Ⅲ (the specific stage was unknown). As of October 1, 2022, 12 patients (50.0%) had completed the protocol for one year. Of the 24 patients, 5 (20.8%) patients relapsed. The The 1-year recurrence-free survival (RFS) rate was 76.2% (95% CI: 65.2%-87.2%). In the cutaneous melanoma subgroup, the 1-year RFS rate was 81.6% (95% CI: 71.6%-91.6%). Two patients relapsed during adjuvant therapy, and three patients relapsed after completing the protocol. Twenty patients (83.3%) reported at least one adverse event, of which 7 patients (29.2%) had grade 3 or grade 4 serious adverse reactions. The most common adverse reactions were fever, fatigue and nausea. Panniculitis occurred in 4 patients, mainly involving thighs and upper limbs. One patient (4.2%) permanently stopped taking the drug due to adverse events, the dose was adjusted in 2 patients (8.3%) due to adverse events, and drug treatment was interrupted in 7 patients (29.2%) due to adverse events. Conclusion: This study confirmed the short-term benefit and good tolerance of the adjuvant therapy with dabrafenib combined with trametinib in Chinese patients with stage Ⅲ melanoma with BRAFV600 mutation.http://www.china-oncology.com/fileup/1007-3639/PDF/1675314921307-882219677.pdf|malignant melanoma|adjuvant therapy|targeted therapy|effectiveness|safety |
| spellingShingle | JIA Dongdong, LI Tao Retrospective analysis of adjuvant therapy with dabrafenib and trametinib for 24 patients with malignant melanoma Zhongguo aizheng zazhi |malignant melanoma|adjuvant therapy|targeted therapy|effectiveness|safety |
| title | Retrospective analysis of adjuvant therapy with dabrafenib and trametinib for 24 patients with malignant melanoma |
| title_full | Retrospective analysis of adjuvant therapy with dabrafenib and trametinib for 24 patients with malignant melanoma |
| title_fullStr | Retrospective analysis of adjuvant therapy with dabrafenib and trametinib for 24 patients with malignant melanoma |
| title_full_unstemmed | Retrospective analysis of adjuvant therapy with dabrafenib and trametinib for 24 patients with malignant melanoma |
| title_short | Retrospective analysis of adjuvant therapy with dabrafenib and trametinib for 24 patients with malignant melanoma |
| title_sort | retrospective analysis of adjuvant therapy with dabrafenib and trametinib for 24 patients with malignant melanoma |
| topic | |malignant melanoma|adjuvant therapy|targeted therapy|effectiveness|safety |
| url | http://www.china-oncology.com/fileup/1007-3639/PDF/1675314921307-882219677.pdf |
| work_keys_str_mv | AT jiadongdonglitao retrospectiveanalysisofadjuvanttherapywithdabrafenibandtrametinibfor24patientswithmalignantmelanoma |